NASDAQ:FLXN - Flexion Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$10.95 +0.21 (+1.96 %)
(As of 04/24/2019 04:00 PM ET)
Previous Close$10.74
Today's Range$10.39 - $11.06
52-Week Range$9.90 - $29.10
Volume445,155 shs
Average Volume673,134 shs
Market Capitalization$416.02 million
P/E RatioN/A
Dividend YieldN/A
Beta1.68
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States. The company also develops FX201 a gene therapy product candidate designed to stimulate the production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts.

Receive FLXN News and Ratings via Email

Sign-up to receive the latest news and ratings for FLXN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FLXN
CUSIPN/A
Phone781-305-7777

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$22.52 million
Book Value$2.91 per share

Profitability

Net Income$-169,660,000.00
Net Margins-753.24%

Miscellaneous

Employees272
Market Cap$416.02 million
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable

Flexion Therapeutics (NASDAQ:FLXN) Frequently Asked Questions

What is Flexion Therapeutics' stock symbol?

Flexion Therapeutics trades on the NASDAQ under the ticker symbol "FLXN."

How were Flexion Therapeutics' earnings last quarter?

Flexion Therapeutics Inc (NASDAQ:FLXN) announced its quarterly earnings data on Tuesday, August, 7th. The specialty pharmaceutical company reported ($1.16) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($1.22) by $0.06. The specialty pharmaceutical company had revenue of $3.80 million for the quarter, compared to analyst estimates of $3.96 million. Flexion Therapeutics had a negative return on equity of 102.16% and a negative net margin of 753.24%. View Flexion Therapeutics' Earnings History.

When is Flexion Therapeutics' next earnings date?

Flexion Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, May 14th 2019. View Earnings Estimates for Flexion Therapeutics.

What price target have analysts set for FLXN?

7 equities research analysts have issued 12 month price targets for Flexion Therapeutics' shares. Their predictions range from $11.49 to $36.00. On average, they anticipate Flexion Therapeutics' share price to reach $24.2483 in the next year. This suggests a possible upside of 121.4% from the stock's current price. View Analyst Price Targets for Flexion Therapeutics.

What is the consensus analysts' recommendation for Flexion Therapeutics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Flexion Therapeutics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Flexion Therapeutics.

What are Wall Street analysts saying about Flexion Therapeutics stock?

Here are some recent quotes from research analysts about Flexion Therapeutics stock:
  • 1. Northland Securities analysts commented, "We believe Zilretta’s superior safety and efficacy vs. IR-corticosteroids will make it the intra-articular injection of choice for treating OAK and other indications. We anticipate approval of the sNDA for repeat administration for OAK in mid-October. This, along w/ Zilretta receipt of J code (J3304) effective Co.’s pursuit of additional indications, i.e., hip and shoulder, we believe will support peak US sales >$750MM. Flexion reported 4Q Zilretta sales of $9.5MM, aligned w/ consensus. R&D and SG&A expense line items for the 4Q period totaled $14.9MM and $30.6MM, respectively, w/ EPS for the 4Q period at ($1.07) vs. the ($1.15) consensus." (3/1/2019)
  • 2. According to Zacks Investment Research, "Flexion Therapeutics, Inc. is a specialty pharmaceutical company. It is focused on the development and commercialization of injectable pain therapies. The Company is targeting anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It operates in the United States. The Company's product candidate, FX006, is an injectable intra-articular, meaning in the joint, sustained-release treatment for patients with moderate to severe OA pain. It is developing two additional product candidates, FX007 for post-operative pain and FX005 to treat end-stage OA patients. Flexion Therapeutics, Inc. is headquartered in Burlington, Massachusetts. " (2/27/2019)

Has Flexion Therapeutics been receiving favorable news coverage?

Headlines about FLXN stock have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Flexion Therapeutics earned a news impact score of 1.7 on InfoTrie's scale. They also assigned press coverage about the specialty pharmaceutical company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the company's share price in the next few days.

Who are some of Flexion Therapeutics' key competitors?

What other stocks do shareholders of Flexion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Flexion Therapeutics investors own include Regulus Therapeutics (RGLS), Synergy Pharmaceuticals (SGYP), Aduro BioTech (ADRO), Verastem (VSTM), Cara Therapeutics (CARA), Celgene (CELG), Omeros (OMER), TherapeuticsMD (TXMD), AcelRx Pharmaceuticals (ACRX) and Gilead Sciences (GILD).

Who are Flexion Therapeutics' key executives?

Flexion Therapeutics' management team includes the folowing people:
  • Dr. Michael D. Clayman, Co-Founder, Pres, CEO & Director (Age 67)
  • Dr. Neil Bodick, Co-Founder & Chief Scientific Officer (Age 72)
  • Mr. Mark S. Levine, Gen. Counsel & Sec. (Age 46)
  • Mr. David A. Arkowitz, Chief Financial Officer (Age 58)
  • Scott Young, VP of Corp. Communications & Investor Relations

Who are Flexion Therapeutics' major shareholders?

Flexion Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Peregrine Capital Management LLC (1.99%), Selz Capital LLC (0.76%) and Rhenman & Partners Asset Management AB (0.31%). Company insiders that own Flexion Therapeutics stock include David Arkowitz, Mark S Levine, Mark Stejbach, Michael D Clayman, Neil Bodick and Yamo Deniz. View Institutional Ownership Trends for Flexion Therapeutics.

Which major investors are selling Flexion Therapeutics stock?

FLXN stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB and Peregrine Capital Management LLC. Company insiders that have sold Flexion Therapeutics company stock in the last year include Mark S Levine, Michael D Clayman and Neil Bodick. View Insider Buying and Selling for Flexion Therapeutics.

Which major investors are buying Flexion Therapeutics stock?

FLXN stock was bought by a variety of institutional investors in the last quarter, including Selz Capital LLC. Company insiders that have bought Flexion Therapeutics stock in the last two years include David Arkowitz, Mark Stejbach, Michael D Clayman, Neil Bodick and Yamo Deniz. View Insider Buying and Selling for Flexion Therapeutics.

How do I buy shares of Flexion Therapeutics?

Shares of FLXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Flexion Therapeutics' stock price today?

One share of FLXN stock can currently be purchased for approximately $10.95.

How big of a company is Flexion Therapeutics?

Flexion Therapeutics has a market capitalization of $416.02 million and generates $22.52 million in revenue each year. The specialty pharmaceutical company earns $-169,660,000.00 in net income (profit) each year or ($4.49) on an earnings per share basis. Flexion Therapeutics employs 272 workers across the globe.

What is Flexion Therapeutics' official website?

The official website for Flexion Therapeutics is http://www.flexiontherapeutics.com.

How can I contact Flexion Therapeutics?

Flexion Therapeutics' mailing address is 10 MALL ROAD SUITE 301, BURLINGTON MA, 01803. The specialty pharmaceutical company can be reached via phone at 781-305-7777 or via email at [email protected]


MarketBeat Community Rating for Flexion Therapeutics (NASDAQ FLXN)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  465 (Vote Outperform)
Underperform Votes:  266 (Vote Underperform)
Total Votes:  731
MarketBeat's community ratings are surveys of what our community members think about Flexion Therapeutics and other stocks. Vote "Outperform" if you believe FLXN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FLXN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/24/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel